This company is developing some new technology to increase GDNF production in the brain. GDNF has shown success in reversing symptoms of people with PD and a return to 'normal' life. I personally think this is the way to go and it gives me hope and I think it will for you too. This technology combined with fast walking may give us what we are looking for.
Company developing new way to increase GD... - Cure Parkinson's
Company developing new way to increase GDNF in the brain which may reverse PD
![rhenry45 profile image](https://images.hu-production.be/avatars/3a72542ae9cb25729a4691dff7338807_small@2x_100x100.jpg)
![rhenry45 profile image](https://images.hu-production.be/avatars/3a72542ae9cb25729a4691dff7338807_small@2x_100x100.jpg)
This DOES sound promising, although sometimes these possible cures seem to drop off the radar. I sure hope this one is going to succeed!!
Thanks for posting the link.
I don't want to rain on anyone's parade, but after listening to this recent podcast,
soundcloud.com/world-parkin...
the conclusion seems to be that Growth Factors is a story again of "high hopes and dashed expectations." The goal of "stopping the disease," is still eluding our grasp. Although the message on GDNF is disappointing, the tape tells a fascinating story.
Delivery of the GDNF is not the only problem. Two other, more basic obstacles, are in the way, rendering the GDNF ineffective: a) by 5 years after diagnosis, too few dopamine neurons to be reinvigorated are left alive, and b) alpha synuclein "gums up the dopamine receptors."
But it's not a dead-end. The expert interviewed, Dr. Jeffrey Kordower, mentions some new research targets that now look promising, and which focus on other symptoms that go beyond dopamine, in particular, balance and dementia.
I agree with you that neurogenisis seems the way forward but we can encourage this ourselves. We don't need some company to make a mint by producing an artificial stimulant. Read Dr Brant Cortright "Neurogenisis diet and lifestyle".
Thank you for sharing this info
"Medicxi will invest up to €9m ($10m) in the asset-centric company *to show clinical efficacy* " - meaning they have not started human studies. This has to go through phase 1, 2, & 3 testing to get approved and they have not even started. Further down in the article we see: " "An mGluR4 PAM is ready to enter Phase II at Prexton Therapeutics " - well, that's not quite right, they are still in phase 1, so they are a little bit ahead: prextontherapeutics.com/